Quick answers
- What is Cholestyramine used for?
- The FDA-approved label (Questran, Par Health USA, LLC, April 17, 2026) says: “1) QUESTRAN (Cholestyramine for Oral Suspension USP), is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Cholestyramine have a boxed warning?
- No. None of the 34 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Cholestyramine?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Cholestyramine been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Cholestyramine?
- 15 companies list prescription products of Cholestyramine in the FDA NDC Directory, including Bryant Ranch Prepack, Epic Pharma, LLC and Par Health USA, LLC.
What Cholestyramine is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
1) QUESTRAN (Cholestyramine for Oral Suspension USP), is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. …
— FDA label: Questran, Par Health USA, LLC, effective April 17, 2026. Read the full label on DailyMed →
The FDA has 34 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
0 of 34 FDA labels for this medicine have a boxed warning.
Forms and how it is given
| Dosage forms | Powder, for suspension · Powder |
|---|---|
| Route | Oral |
| Prescription products | 39 in the FDA NDC Directory |
| Brand names | Questran, Prevalite, Cholestyramine Light |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| cholestyramine 4 g/4.8 g powder, for suspension | Generic | $0.8638 per unit |
| cholestyramine 4 g/4.8 g powder, for suspension | Generic | $0.1454 per gram |
| cholestyramine 4 g/5 g powder, for suspension | Generic | $0.8638 per unit |
| cholestyramine 4 g/5 g powder, for suspension | Generic | $0.2827 per gram |
| cholestyramine 4 g/5.5 g powder, for suspension | Generic | $0.8638 per unit |
| cholestyramine 4 g/5.5 g powder, for suspension | Generic | $0.1633 per gram |
| cholestyramine 4 g/5.7 g powder | Generic | $0.1158 per gram |
| cholestyramine 4 g/5.7 g powder, for suspension | Generic | $0.8638 per unit |
| cholestyramine 4 g/5.7 g powder, for suspension | Generic | $0.1158 per gram |
| cholestyramine 4 g/5.718 g powder, for suspension | Generic | $0.8638 per unit |
| cholestyramine 4 g/8.78 g powder, for suspension | Generic | $0.9031 per unit |
| cholestyramine 4 g/8.78 g powder, for suspension | Generic | $0.0837 per gram |
| cholestyramine 4 g/9 g powder | Generic | $0.0954 per gram |
| cholestyramine 4 g/9 g powder, for suspension | Generic | $0.9031 per unit |
| cholestyramine 4 g/9 g powder, for suspension | Generic | $0.0954 per gram |
NADAC list of November 4, 2026; these prices took effect between November 19, 2025 and October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Bryant Ranch Prepack8 products
- Epic Pharma, LLC6 products
- Par Health USA, LLC4 products
- Puracap Laboratories LLC dba Blu Pharmaceuticals3 products
- Chartwell RX, LLC2 products
- Ascend Laboratories, LLC2 products
- Precision Dose, Inc.2 products
- Zydus Pharmaceuticals USA Inc.2 products
- Macleods Pharmaceuticals Limited2 products
- TAGI Pharma, Inc.2 products
- Zydus Lifesciences Limited2 products
- Upsher-Smith Laboratories, LLC1 product
- Ajanta Pharma USA Inc.1 product
- Micro Labs Limited1 product
- AiPing Pharmaceutical, Inc.1 product
FDA approval history
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
Generic approvals (18)
- ANDA073263Aiping Pharm Inc · February 22, 1996
- ANDA074557Epic Pharma LLC · August 15, 1996
- ANDA074558Epic Pharma LLC · August 15, 1996
- ANDA074561Chartwell Rx · August 15, 1996
- ANDA074562Chartwell Rx · August 15, 1996
- ANDA077203Ph Health · August 26, 2005
- ANDA077204Ph Health · August 26, 2005
- ANDA202902Zydus Pharms · April 25, 2017
- ANDA202901Zydus Pharms · July 2, 2018
- ANDA211119Ajanta Pharma Ltd · April 6, 2020
- ANDA209599Pharmobedient Cnsltg · November 12, 2020
- ANDA209597Pharmobedient · March 9, 2021
- ANDA211799Alkem Labs Ltd · October 19, 2021
- ANDA211856Alkem Labs Ltd · October 19, 2021
- ANDA214877Aiping Pharm Inc · January 21, 2022
- ANDA209109Macleods Pharms · October 31, 2024
- ANDA207294Macleods Pharms · November 21, 2024
- ANDA219318Micro Labs · March 5, 2026
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — Questran, Par Health USA, LLC, effective April 17, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →